Database Commons

a catalog of worldwide biological databases

MOTIVATION: Pediatric acute lymphoblastic leukemia (ALL) is the most common cancer among children worldwide. The availability of easily accessible multi-omics data provides unprecedented resources and opportunities for discovering and refining disease biology, cancer biomarkers, and drug mechanisms of action. This has led to exponential growth of omics data available in public repositories. However, delivering the useful information and knowledge extraction from this data is one of the bottlenecks of multi-omics. Presenting, navigating, and downloading ALL omics data in a user-friendly interface provide a valuable platform for biologists and clinicians to get most of the omics data. Our in-house data provides in-depth mass spectrometry-based protein abundance data for a large panel of commercially available ALL cell lines. Providing this data to the scientific community in the form of a user-friendly web-portal allows for easy and detailed exploration of the data.
RESULTS: We have developed the Functional Omics Resource of Acute Lymphoblastic Leukemia (FORALL) web-portal. FORALL is a shiny-based web portal designed to navigate in-depth mass spectrometry-based proteomics data of 51 cell lines. The proteomics data can be navigated and visualized along with matched RNA expression data as well as drug sensitivity data of 528 investigational and approved drugs.
AVAILABILITY AND IMPLEMENTATION: FORALL is available at https://proteomics.se/forall/.

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Although standard-of-care chemotherapeutics are sufficient for most ALL cases, there are subsets of patients with poor response who relapse in disease. The biology underlying differences between subtypes and their response to therapy has only partially been explained by genetic and transcriptomic profiling. Here, we perform comprehensive multi-omic analyses of 49 readily available childhood ALL cell lines, using proteomics, transcriptomics, and pharmacoproteomic characterization. We connect the molecular phenotypes with drug responses to 528 oncology drugs, identifying drug correlations as well as lineage-dependent correlations. We also identify the diacylglycerol-analog bryostatin-1 as a therapeutic candidate in the MEF2D-HNRNPUL1 fusion high-risk subtype, for which this drug activates pro-apoptotic ERK signaling associated with molecular mediators of pre-B cell negative selection. Our data is the foundation for the interactive online Functional Omics Resource of ALL (FORALL) with navigable proteomics, transcriptomics, and drug sensitivity profiles at https://proteomics.se/forall .